Monitoring of Progesterone Administered in Infertile Patients During a Cycle of Frozen Embryo Transfer.

Monitoring of Progesterone Administered in Infertile Patients During a Cycle of Frozen Embryo Transfer: a Population Pharmacokinetic Study.

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05109676

Acronym

PEKAPROGE

Enrollment

300

Registered

2021-11-05

Start date

2021-12-07

Completion date

2022-06-03

Last updated

2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IVF

Brief summary

During an In Vitro Fertilization (IVF) attempt, several embryos are obtained but not all of them can be transferred to the uterus in the same cycle due to the risk of multiple pregnancies. Thus, it is very common for these couples to benefit from cryopreservation. Patients scheduled for frozen embryo transfer (TEC) receive estrogen and progesterone replacement therapy to prepare the endometrium for implantation. Data from the literature recently showed that low progesterone on the day of embryo transfer was responsible for a significantly higher rate of implantation failure and miscarriage.

Interventions

OTHERQuestionnaire

A questionnaire will be offered to patients and identify the schedules of administration of progesterone, the day and time of blood samples taken as part of the care, the potential adverse events associated with this administration.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patient undergoing a frozen embryo transfer in an artificial cycle at the AMP center of the Toulouse University Hospital. * Affiliation to a social security scheme or equivalent * Patient fulfilling the conditions for access to the AMP according to French bioethics law * Patient having given her consent (oral or written) after clear and fair information

Exclusion criteria

* Patient who received intramuscular administration of progesterone during the endometrial preparation phase. * Patient with comprehension difficulties. * Protected adult patient (safeguard of justice, guardianship or curatorship)

Design outcomes

Primary

Measure	Time frame	Description
Average plasma progesterone concentration.	Day of embryo transfer.	Dosage of apparent clearance (CL/F)

Countries

France

Contacts

PRINCIPAL_INVESTIGATORNicolas Gatimel, MD

University Hospital, Toulouse

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026